Repurposing of Rutan showed effective treatment for COVID-19 disease

Previously, from the tannic sumac plant ( ), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses, adenoviruses, paramyxoviruses, herpes virus, and cytomegalovirus. Here, our re-purposing study demonstrated that Rutan at 25, 50, and 100 mg/kg provi...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in medicine Vol. 10; p. 1310129
Main Authors:	Salikhov, Shavkat I, Abdurakhmonov, Ibrokhim Y, Oshchepkova, Yuliya I, Ziyavitdinov, Jamolitdin F, Berdiev, Nodir Sh, Aisa, Haji Akber, Shen, Jingshan, Xu, Yechun, Xu, H Eric, Jiang, Xiangrui, Zhang, Leike, Vypova, Natalia L, Allaberganov, Dilshod Sh, Tagayalieva, Nigora A, Musabaev, Erkin I, Ibadova, Gulnara A, Rajabov, Ilxom B, Lokteva, Lyubov M
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 29-11-2023
Subjects:	3CLpro COVID-19 Medicine RdRp Rhus coriaria Rutan SARS-CoV-2 COVID-19 clinical trial Rhus coriaria SARS-CoV-2 Rutan RdRp 3CLpro
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Previously, from the tannic sumac plant ( ), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses, adenoviruses, paramyxoviruses, herpes virus, and cytomegalovirus. Here, our re-purposing study demonstrated that Rutan at 25, 50, and 100 mg/kg provided a very effective and safe treatment for COVID-19 infection, simultaneously inhibiting two vital enzyme systems of the SARS-CoV-2 virus: 3C-like proteinase (3CLpro) and RNA-dependent RNA polymerase (RdRp). There was no drug accumulation in experimental animals' organs and tissues. A clinical study demonstrated a statistically significant decrease in the C-reactive protein and a reduction of the viremia period. In patients receiving Rutan 25 mg (children) and 100 mg (adults), the frequency of post-COVID-19 manifestations was significantly less than in the control groups not treated with Rutan tablets. Rutan, having antiviral activity, can provide safe treatment and prevention of COVID-19 in adults and children. ClinicalTrials.gov, ID NCT05862883.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Shi Xue Dai, Guangdong Provincial People’s Hospital, China; Zhonglei Wang, Qufu Normal University, China Edited by: Liyan Yang, Qufu Normal University, China
ISSN:	2296-858X 2296-858X
DOI:	10.3389/fmed.2023.1310129